36 related articles for article (PubMed ID: 35900907)
21. HLA-DR antigen-negative acute myeloid leukemia.
Wetzler M; McElwain BK; Stewart CC; Blumenson L; Mortazavi A; Ford LA; Slack JL; Barcos M; Ferrone S; Baer MR
Leukemia; 2003 Apr; 17(4):707-15. PubMed ID: 12682628
[TBL] [Abstract][Full Text] [Related]
22. Expression and clinical significance of SNAI1 and ZEB1 genes in acute myeloid leukemia patients.
Shousha WG; Ramadan SS; El-Saiid AS; Abdelmoneim AE; Abbas MA
Mol Biol Rep; 2019 Aug; 46(4):4625-4630. PubMed ID: 31055699
[TBL] [Abstract][Full Text] [Related]
23. CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations.
Gajendra S; Gupta R; Thakral D; Gupta SK; Jain G; Bakhshi S; Sharma A; Sahoo RK; Kumar L; Rai S; Singh S; Upadhyay AD
Int J Lab Hematol; 2023 Apr; 45(2):221-228. PubMed ID: 36504282
[TBL] [Abstract][Full Text] [Related]
24. [Clinical analysis of HLA-DR-negative non-M3 AML].
Mori H; Sakai H; Sanada M; Shimamoto K; Sasaki S; Azuma R; Higuchi T; Harada H; Niikura H; Omine M; Fujita K; Takahashi N
Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
[TBL] [Abstract][Full Text] [Related]
25. Advantages of nanomedicine over the conventional treatment in Acute myeloid leukemia.
Janani G; Girigoswami A; Girigoswami K
J Biomater Sci Polym Ed; 2024 Feb; 35(3):415-441. PubMed ID: 38113194
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow overexpression of SNAI1 is an early indicator of intrinsic drug resistance in patients with de novo acute myeloid leukemia.
Gouda MBY; Hassan NM; Kandil EI
J Gene Med; 2023 May; 25(5):e3443. PubMed ID: 35900907
[TBL] [Abstract][Full Text] [Related]
27. Adult acute leukemia.
Cripe LD
Curr Probl Cancer; 1997; 21(1):1-64. PubMed ID: 9058027
[TBL] [Abstract][Full Text] [Related]
28. Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA double mutation: A case report and review of the literature.
Sun Y; Wang C; Sun Y; Wang J; Rong C; Wu A; Ouyang G; Sheng L
Medicine (Baltimore); 2021 Feb; 100(5):e24385. PubMed ID: 33592885
[TBL] [Abstract][Full Text] [Related]
29. Induction of retinoid resistance by all-trans retinoic acid in acute promyelocytic leukemia after remission.
Cornic M; Chomienne C
Leuk Lymphoma; 1995 Jul; 18(3-4):249-57. PubMed ID: 8535190
[TBL] [Abstract][Full Text] [Related]
30. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
31. The unique aspects of acute promyelocytic leukemia.
Stone RM; Mayer RJ
J Clin Oncol; 1990 Nov; 8(11):1913-21. PubMed ID: 2230879
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
